Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Haferkamp

Showing results (41-50 of 149) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|December 27, 2018
Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samplesKathrin Weidele, Nataša Stojanović, Giancarlo Feliciello, et al.
Oncotarget|April 29, 2016
RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cellsSonja Hesbacher, Lisa Pfitzer, Katharina Wiedorfer, et al.
Annals of Hematology|April 21, 2025
Paraneoplastic leukocytoclastic vasculitis mimicking ulcus cruris as rare initial manifestation of smoldering myeloma IgG kappaChristina Brummer, Kirsten Utpatel, Sebastian Geis, et al.
Cancer Letters|July 20, 2017
BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell linesAndreas Borst, Sebastian Haferkamp, Johannes Grimm, et al.
Journal of Cutaneous Pathology|October 12, 2013
Periocular cutaneous oncocytoma with signs of disrupted oxygen metabolismMarion Wobser, Sebastian Haferkamp, Sabine Roth, et al.
Nature Communications|June 27, 2017
Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppressionGiada Dogliotti, Lars Kullmann, Pratibha Dhumale, et al.
Advances in Therapy|July 9, 2020
Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of ChoiceSebastian Haferkamp, Mareike Alter, Dirk Debus, et al.
The British Journal of Dermatology|September 4, 2025
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II studySebastian Haferkamp, Bastian Schilling, Carola Berking, et al.
ERJ Open Research|May 19, 2021
Sleep apnoea and incident malignancy in type 2 diabetesSarah Driendl, Michael Arzt, Claudia S Zimmermann, et al.
Plos One|January 30, 2014
p53 regulation by TRP2 is not pervasive in melanomaRoland Houben, Corinna P Schmid, Melissa Maier, et al.
Pageof 15

Showing results (41-50 of 149) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|December 27, 2018
Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samplesKathrin Weidele, Nataša Stojanović, Giancarlo Feliciello, et al.
Oncotarget|April 29, 2016
RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cellsSonja Hesbacher, Lisa Pfitzer, Katharina Wiedorfer, et al.
Annals of Hematology|April 21, 2025
Paraneoplastic leukocytoclastic vasculitis mimicking ulcus cruris as rare initial manifestation of smoldering myeloma IgG kappaChristina Brummer, Kirsten Utpatel, Sebastian Geis, et al.
Cancer Letters|July 20, 2017
BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell linesAndreas Borst, Sebastian Haferkamp, Johannes Grimm, et al.
Journal of Cutaneous Pathology|October 12, 2013
Periocular cutaneous oncocytoma with signs of disrupted oxygen metabolismMarion Wobser, Sebastian Haferkamp, Sabine Roth, et al.
Nature Communications|June 27, 2017
Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppressionGiada Dogliotti, Lars Kullmann, Pratibha Dhumale, et al.
Advances in Therapy|July 9, 2020
Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of ChoiceSebastian Haferkamp, Mareike Alter, Dirk Debus, et al.
The British Journal of Dermatology|September 4, 2025
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II studySebastian Haferkamp, Bastian Schilling, Carola Berking, et al.
ERJ Open Research|May 19, 2021
Sleep apnoea and incident malignancy in type 2 diabetesSarah Driendl, Michael Arzt, Claudia S Zimmermann, et al.
Plos One|January 30, 2014
p53 regulation by TRP2 is not pervasive in melanomaRoland Houben, Corinna P Schmid, Melissa Maier, et al.
Pageof 15